NeuroVive announced the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the US Food and Drug Administration ...
The positive outcome from the clinical phase IIa CHIC study and the preclinical studies have now convinced NeuroVive to proceed into the next stage of clinical development.